Combination with portosystemic shunt occlusion and antiviral therapy improves prognosis of decompensated cirrhosis. Issue 4 (4th March 2020)

• Record Type: Journal Article
• Authors: Tamai, Hideyuki; Minamiguchi, Hiroki; Ida, Yoshiyuki; Shingaki, Naoki; Muroki, Tokuro; Maeshima, Shuya; Shimizu, Ryo; Okamura, Junpei; Koyama, Takao; Nakao, Taisei; Sonomura, Tetsuo
• Is Part Of: JGH open. Volume 4:Issue 4(2020)
• Page Start: 670
• Page End: 676
• Publication Date: 2020-03-04
• Subjects: decompensated cirrhosis -- portosystemic shunt -- viral hepatitis
• DOI: 10.1002/jgh3.12319
• Languages: English
• ISSNs: 2397-9070

Abstract

Abstract: Background and Aim: Portosystemic shunt occlusion using endovascular treatment can transiently improve liver function in patients with decompensated cirrhosis. In recent years, viral hepatitis can be easily controlled. The present study aimed to clarify the safety and efficacy of endovascular treatment in decompensated cirrhotic patients, and to elucidate whether viral treatment improves the prognosis after shunt occlusion. Methods: Among 98 cirrhotic patients who received portosystemic shunt occlusion from January 2007 to June 2016, we retrospectively analyzed 61 decompensated cirrhotic patients. Results: Forty‐five patients had viral hepatitis. Recovery rates of liver function to Child A within 6 months in viral hepatitis, non‐viral hepatitis, and overall were 78% (35/45), 81% (13/16), and 79% (48/61), respectively. Recovery rates according to baseline Child‐Pugh score were as follows: score 7, 88% (15/17); score 8, 89% (24/27); score 9, 69% (9/13); and score ≥ 10, 0% (0/4). Three‐year reprogression rates to decompensated cirrhosis for non‐virus, non‐sustained viral negativity (SVN), and SVN groups were 23 100, and 0%, respectively ( P < 0.01). Three‐year survival rates for those were 63, 62, and 91%, respectively ( P < 0.01). Eight‐year survival rate for SVN group was also 91%. Multivariate analysis revealed age, baseline ammonia level, baseline Child class, and SVN as independent contributors to survival. Conclusions: SVN in patients with viral hepatitis appears prerequisite to maintaining recovered liver function by shunt occlusion and to improving prognosis. Combination therapy with shunt occlusion and antiviral treatment should be considered as a first‐line treatment for decompensated cirrhotic patients with viral hepatitis and large portosystemic shunt growth. Abstract : Portosystemic shunt occlusion using endovascular treatment was safe and effective for patients with decompensated cirrhosis. The recovered liver function by shunt occlusion was maintained for a long time in patients who received antiviral therapy, and their long‐term prognosis is very good.